InvestorsHub Logo
Followers 51
Posts 9121
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 11/14/2022 9:25:44 AM

Monday, November 14, 2022 9:25:44 AM

Post# of 13510
MODERNA'S BA.4/BA.5 TARGETING BIVALENT BOOSTER, MRNA-1273.222, MEETS PRIMARY ENDPOINT OF SUPERIORITY AGAINST OMICRON VARIANTS COMPARED TO BOOSTER DOSE OF MRNA-1273 IN PHASE 2/3 CLINICAL TRIAL


https://investors.modernatx.com/news/news-details/2022/Modernas-BA.4BA.5-Targeting-Bivalent-Booster-mRNA-1273.222-Meets-Primary-Endpoint-of-Superiority-Against-Omicron-Variants-Compared-to-Booster-Dose-of-mRNA-1273-in-Phase-23-Clinical-Trial/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News